Table 2.

Median durations and corresponding 90th percentiles and interquartile ranges (IQR) for time from physician visit to genetic counseling by program year, age group, prior breast cancer, and risk criteria for women who had genetic counseling and testing (N = 8,444)

Physician referral to genetic counseling	Women with known genetic assessment outcome	Included womena	Median (days)	IQR (days)	90th Percentile (days)	p‐Value
Program year
2011–2012 (reference)	1,854	1,022	57	14–119	191	—
2012–2013	2,162	1,409	48	3–110	194	.002
2013–2014	2,187	1,496	44	6–107	168	.0009
2014–2015	2,241	1,540	53	10–117	202	.49
Age groupb
30–49 years (reference)	3,781	2,506	48	8–109	184	—
50–69 years	4,663	2,961	54	8–113	190	.29
Prior breast cancer
No (reference)	6,854	4,588	49	7–107	183	—
Yes	1,590	879	62	12–135	208	<.0001
Risk criteriac
Gene mutation carrier (reference)	1,278	764	39	4–100	185	—
Family history and ≥25% riskd	535	349	78	22–147	227	<.0001
1st degree relative of a mutation carrier, declined genetic testing	27	22	20	0–70	92	.11
Ineligible for high risk screening	6,604	4,332	51	8–111	183	.002

^aExcludes women who had genetic counseling prior to their physician visit date (n = 2,781) or women who had >365 days between physician visit and genetic counseling dates (n = 196).

^bAt time of High Risk OBSP referral.

^cIf a woman met more than one risk criterion after genetic assessment, the following hierarchy was selected: carrier of a deleterious gene mutation, family history and ≥25% lifetime risk, first‐degree relative of a mutation carrier (but declined genetic testing).

^dBased on International Breast Cancer Intervention Study (IBIS) and/or Breast and Ovarian Analysis of Disease Incidence of Carrier Estimation Algorithm (BOADICEA).